相关临床试验
201
27 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2004
进行中（未招募）
11
5.5%
已完成
106
52.7%
Enrolling By Invitation
1
0.5%
尚未招募
15
7.5%
招募中
29
14.4%
暂停
1
0.5%
终止
8
4.0%
Unknown
25
12.4%
撤回
5
2.5%
暂无批准数据
- Cancer Research UK has awarded a £2.5 million, five-year grant to fund the next phase of an ovarian cancer research programme led by Prof Stephen Taylor at The University of Manchester. - The laboratory houses the largest resource of living ovarian cancer cell cultures of its kind in the world, enabling researchers to identify new drug-targetable weaknesses. - The programme aims to develop better treatment options and move toward more personalised treatment for women with ovarian cancer. - Cancer survivor Gemma Coleman, who underwent surgical menopause at 34 after ovarian and womb cancer, welcomed the funding as a source of hope for future patients.
- A new MRC Centre of Research Excellence in Mitochondrial Genome Therapeutics has been established, led by the University of Cambridge with partners across the UK, Europe, and Australia. - The centre aims to define how mitochondrial DNA mutations cause disease and translate that knowledge into new therapeutic approaches for conditions affecting around 1 in 5,000 people. - The University of Manchester team will develop next-generation base editing tools to selectively target the most common disease-causing mtDNA mutations. - Currently no cure exists for mitochondrial diseases, which can cause severe disability, progressive decline, and premature death.
- University of Manchester researchers demonstrated a boron-based super chaotropic nanostructure that transports hydrophilic glycans directly into mammalian cells, eliminating the need for cytotoxic organic solvents such as DMSO. - The method enabled metabolic oligosaccharide engineering to "edit" cell surfaces and investigate recently discovered glycoRNA, opening new avenues in glycobiology and cell-surface engineering. - Future work will focus on increasing glycan transport capacity to match the delivery performance of existing acetylation-based methods.
- Greater Manchester has secured £50 million from UKRI's Local Innovation Partnerships Fund to drive innovation-led growth across five major projects. - Two health-focused initiatives—the Greater Data Accelerator (£6.7M) and GM Wearables Cluster (£5.5M)—aim to accelerate medicines adoption and transform remote monitoring technologies. - The GROW AI project (£12.8M) will fast-track AI commercialisation and support SME adoption across the region, including health and life sciences applications. - The funding positions Greater Manchester as the first of 17 UK regions to move into full delivery under this flagship national programme.
- Two independent studies published June 16 demonstrate that AI analysis of routine eye scans can predict risk factors for cardiovascular and neurological diseases, including Alzheimer's, heart failure, and Parkinson's. - University of Manchester researchers developed "Ret-AAE" using UK Biobank data from over 68,000 people, linking retinal features to genes involved in neurodegenerative pathways and cardiovascular function. - University of Florida scientists showed that machine learning analysis of retinal photographs from over 40,000 patients accurately predicted Alzheimer's risk factors such as blood pressure, smoking, alcohol use, and insomnia. - Both studies highlight the potential for widely available, low-cost high-street eye exams to serve as accessible health screening tools for disease prevention before symptoms appear.
- University of Oxford researchers gain MRC funding and access to the DAWN supercomputer to develop AI-designed personalised mRNA cancer vaccines through the UK Cancer Vaccine AI & Supercomputing Project. - Cancer Research UK increases annual investment in its Manchester Institute by £6 million, bringing total funding to over £17 million, to expand immunology, immunotherapy, and AI-powered cancer research. - The Oxford-led consortium, now over 2,500 members, uses the CIARA AI scientist platform to analyse tumour biology and predict vaccine targets capable of generating strong anti-cancer immune responses. - The Manchester funding will create up to 100 new research jobs and support studies into how inflammation, the gut microbiome, and lab-grown white blood cells influence cancer treatment outcomes.
- INBRAIN Neuroelectronics successfully completed patient enrollment for its first-in-human study of a graphene-based cortical interface, with eight of ten recruited patients undergoing surgery without any device failures or safety issues. - The ultra-thin, flexible graphene electrodes demonstrated superior performance compared to conventional rigid electrodes, successfully capturing high-resolution brain signals during awake surgeries where patients performed tasks like naming objects. - The study enters a 90-day follow-up phase with full results expected later this year, marking a significant advancement toward commercializing next-generation brain-computer interface systems for neurological disorders.
- Researchers at the University of Manchester have developed a blood test using two protein markers that can detect glioblastoma with over 96% accuracy, potentially revolutionizing early diagnosis. - The test identifies coagulation factor IX (F9) and cartilage oligomeric matrix protein (COMP) in blood samples, providing a stable and robust signal despite tumor genetic diversity. - Clinical trials are now underway at six UK sites and four international locations, with hopes of developing a simple diagnostic device similar to a COVID test. - The breakthrough could reduce reliance on invasive surgical biopsies and MRI scans, enabling real-time monitoring of treatment response and disease progression.
- Eli Lilly has initiated the SURMOUNT-REAL UK trial, a five-year randomized study evaluating tirzepatide's long-term effectiveness in primary care settings with up to 3,000 participants in Greater Manchester. - The trial will assess tirzepatide's impact on obesity outcomes, type 2 diabetes prevention, and broader healthcare measures including quality of life, work productivity, and hospital visits. - Concurrently, Lilly announced price reductions for tirzepatide single-dose vials in the US through its LillyDirect platform to improve access to obesity treatments.
- Three-year-old Oliver Chu became the first person globally to receive groundbreaking gene therapy for Hunter syndrome, a rare genetic disorder that typically causes death before age 20. - Nine months post-treatment, Oliver is producing hundreds of times the normal amount of the missing enzyme and showing dramatic improvements in speech, mobility, and cognitive development. - The Manchester-based trial involves five boys worldwide and represents a potential breakthrough for treating rare genetic conditions affecting over 3.5 million people in the UK. - The gene therapy uses modified stem cells to produce the missing iduronate-2-sulfatase enzyme, with modifications allowing it to cross the blood-brain barrier effectively.
